Detalhe da pesquisa
1.
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
N Engl J Med
; 385(3): 228-238, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34260836
2.
Quantitative assessment of adverse events in clinical trials: Comparison of methods at an interim and the final analysis.
Biom J
; 62(3): 658-669, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31756032
3.
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.
Blood
; 123(12): 1833-5, 2014 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24443442
4.
Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study.
Blood
; 131(2): 263-265, 2018 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29097381
5.
A novel approach to visualize clinical benefit of therapies for chronic graft versus host disease (cGvHD): the probability of being in response (PBR) applied to the REACH3 study.
Bone Marrow Transplant
; 59(1): 12-16, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37898726
6.
Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial.
BMC Cancer
; 12: 311, 2012 Jul 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-22824201
7.
Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.
Oncologist
; 16(5): 632-40, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21459902
8.
A proof of concept phase II non-inferiority criterion.
Stat Med
; 30(13): 1618-27, 2011 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21351286
9.
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Lancet
; 372(9637): 449-56, 2008 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-18653228
10.
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
Cancer
; 116(18): 4256-65, 2010 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20549832